Tue Mar 10 13:10:00 UTC 2026: ### FDA Approval of Leucovorin for Rare Genetic Disorder Sparks Controversy After Autism Claims
The Story:
The FDA has approved the prescription drug leucovorin for cerebral folate deficiency in the receptor 1 gene, a rare genetic condition affecting approximately 1 in 1 million people. This decision follows a September 2025 White House briefing where President Donald Trump, along with HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary, touted leucovorin as a potential treatment for autism. The FDA’s narrow approval has led to confusion and disappointment among families of autistic children, especially after leucovorin prescriptions surged following the White House briefing, causing shortages.
Key Points:
* The FDA approved leucovorin for cerebral folate deficiency in the receptor 1 gene, a rare genetic condition.
* In September 2025, President Trump and other officials suggested leucovorin could be a treatment for autism, leading to increased demand.
* The approval was based on case studies and literature reviews, not randomized, placebo-controlled trials, due to the rarity of the genetic condition.
* A retracted study on leucovorin’s efficacy in treating autism contributed to the FDA’s decision to limit the approval.
* Prescriptions for leucovorin doubled after the September 2025 briefing, causing shortages and parents to seek unregulated alternatives.
Key Takeaways:
* Political endorsements of medical treatments can have unintended consequences, such as drug shortages and false hope.
* The FDA’s approval process prioritizes scientific evidence, even when dealing with rare diseases.
* Communication about potential medical treatments must be carefully managed to avoid misleading the public.
* The desperation of parents seeking treatments for autism can make them vulnerable to unsubstantiated claims.
* The FDA approval was based on a systematic literature review, “including published case reports with patient-level information, as well as mechanistic data.”
Impact Analysis:
The approval of leucovorin for a rare genetic disorder, while a milestone for those affected, highlights the potential pitfalls of politicizing medical treatments. The surge in prescriptions following the White House briefing demonstrates the power of presidential endorsements and the vulnerability of parents seeking solutions for their children’s conditions. This incident underscores the importance of clear, evidence-based communication from government officials and the FDA to prevent misinformation and ensure responsible use of prescription drugs. The long-term impact could include increased scrutiny of government involvement in promoting specific medical treatments and a greater emphasis on evidence-based medicine in public health messaging.
First Piper 